CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer
Authors:
- William J. DalyWDWilliam J. Daly
- Andrew L. WarshawAWAndrew L. Warshaw
- 1 October 1996
- journal article
- Published by Elsevier in The American Journal of Surgery
- Vol. 172 (4) , 350-352
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Resection Margins in Carcinoma of the Head of the PancreasAnnals of Surgery, 1993
- Pancreatic CarcinomaNew England Journal of Medicine, 1992
- Elevated serum levels of tumor marker CA19-9 in acute cholangitisDigestive Diseases and Sciences, 1988
- Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas.Journal of Clinical Oncology, 1988
- Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancerCancer, 1987
- Intraoperative Electron Beam Irradiation for Patients with Unresectable Pancreatic CarcinomaAnnals of Surgery, 1984